Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Official title

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Study identification

NCT ID

NCT05564377

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 2

Lead sponsor

National Cancer Institute (NCI)

NIH

Enrollment

2,900 participants

Conditions and interventions

Eligibility (public fields only)

Age range

Not listed

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Apr 6, 2023

Primary completion

Jun 30, 2030

Completion

Jun 30, 2030

Last update posted

May 3, 2026

2023 – 2030

United States locations

U.S. sites

475

U.S. states

44

U.S. cities

355

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.